by tony62tiger | September 25, 2020 12:13 pm
Hello Just seeing if my inspired stock sleuthing is correct! Jeff Brown[1] is pitching a cure for childhood blindness, with a 2 year $2000 subscription with a 100% guarantee for CREDIT to another service, money back or nothing as far as I am concerned. So testing with MIT, only company to do human trials and already moving into third stage trials with “CEP290”? as a cure for blindness. Looks very interesting and truly hope it will be successful. The company doing this I think is Editas Medicine and having partnership with Allergen which was recently purchased by Abbvie.
Thoughts anyone?
Source URL: https://www.stockgumshoe.com/2020/09/microblog-jeff-browns-cure-for-blindness/
Copyright ©2024 Stock Gumshoe unless otherwise noted.
It is Editas. They’re in phase 1/2 for edit-101 for LCA10. The study is for Leber congenital amaurosis disease. They dosed their first patient on March 4, 2020 and are expected to give an update of the trial results before the end of the year. The name of the trial is Brilliance. Hope this helps, good luck!